Abstract. Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer, with a 5-year survival rate of <10%; effective drug treatment for ICC is currently lacking. Glucagon-like peptide-1 receptor (GLP-1R) is upregulated in ICC; however, the functions of GLP-1R in ICC remain unknown. In this study, the upregulation of GLP-1R was confirmed in ICC cells using reverse transcription-quantitative polymerase chain reaction and western blot analysis, and GLP-1R was determined to promote the migration and invasion of ICC cells using Transwell assays. This tumor-promoting effect depended on the upregulation of epithelial-mesenchymal transformation-associated proteins, which was mediated by the FoxO1 signaling pathway. It was also indicated that following oxaliplatin treatment, the effects of GLP-1R on EMT and invasion were reversed. This functional reversion was associated with the reduced phosphorylation of S256 in forkhead box O1 (FoxO1) and an increase in the levels of unphosphorylated FoxO1. These findings suggest that incretin-based therapies may increase the risk of ICC metastasis and should not be used solely for the treatment of patients with ICC.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is a form of liver cancer typically diagnosed at advanced stages and with poor prognosis; in the United States its incidence has increased to 3,000 cases annually (1) . Despite the fact that surgery is the preferred treatment for early ICC, only ~35% of patients have early stage disease that may be treated by surgical resection (2, 3) . For patients with advanced stage or unresectable cholangiocarcinoma, the available systemic therapies are of limited effectiveness. The median overall survival time with the current standard of care chemotherapy regimen of gemcitabine and cisplatin is <1 year (3, 4) . Therefore, the identification of novel antitumor targets for ICC is urgently required.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L cells in the distal intestine in response to nutrient ingestion (5, 6) . Upon binding to the GLP-1 receptor (GLP-1R), GLP-1 affects blood glucose levels by stimulating insulin secretion, inhibiting glucagon secretion and gastric emptying, and reducing food intake (7) (8) (9) . Due to its ability to regulate blood glucose levels, GLP-1 is now widely used in clinic for patients with diabetes (10) . In addition to its hypoglycemic effect, GLP-1 alleviates inflammation in intraepithelial lymphocytes of intestinal mucosal epithelium, confers antioxidative and neurogenerative effects in the brain, and protects vascular functions in the cardiovascular system (11) . GLP-1 and GLP-1R-associated signaling also promote tumor progression. Long-term GLP-1R activation was reported to increase the risk of pancreatic cancer development (12) , and GLP-1R agonists were reported to promote neoplastic intestinal growth (13) . In addition, GLP-1-based therapies have been used to treat thyroid carcinoma (14) . It has been previously reported that GLP-1R protein expression is upregulated in ICC and that GLP-1R expression correlated with lymph node metastasis (15) , indicating that GLP-1R is involved in ICC tumor progression. However, Exendin-4 with regards to diabetes, a GLP-1 analog that has similar functions as GLP-1, enhanced oxaliplatin-mediated tumor suppression in ICC (16) . These conflicting data call for an in-depth study on the GLP-1R underlying mechanism of action in ICC.
Forkhead box O1 (FoxO1) is a member of the forkhead box family of transcription factors with a highly conserved DNA-binding domain (17 Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) . Total RNA of all cell lines was extracted from cells using TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The RNA was subsequently reverse transcribed at 95˚C for 10 sec followed by 40 cycles at 95˚C for 5 sec and at 60˚C for 45 sec. The cDNA was used as the template for quantitative PCR using a Takara RNA PCR kit and SYBR Premix Ex Taq (Takara Bio Inc., Otsu, Japan) using Applied Biosystem's 7500 qPCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. GAPDH was used as an internal control. The following primers were used: Human GLP-1R, sense 5'-GGT GCA GAA ATG GCG AGA ATA-3', anti-sense 5'-CCG GTT GCA GAA CAA GTC TGT-3'; human FoxO1, sense 5'-GGA TGT GCA TTC TAT GGT GTA CC-3', anti-sense 5'-TTT CGG GAT TGC TTA TCT CAGAC-3'; human Cadherin 1 (CDH1), sense 5'-CCT AGA TGA ACC TTA TGA GGCCA-3', anti-sense 5'-GCT GTA GAG GAG ACG AGC ATT AT-3'; human GAPDH, sense 5'-GAGTCAACGGATTTGGTCGT-3', anti-sense 5'-TTG ATT TTG GAG GGA TCT CG-3'; human CDH2, sense 5'-TGT ATG TGG GCA AGA TCC ACT-3', anti-sense 5'-CTC GTC GAT CAG GAA GAT GGT-3'; human Snail family transcriptional repressor 1 (SNAI1), sense 5'-TCG GAA GCC TAA CTA CAG CGA-3' , anti-sense 5'-AGA TGA GCA TTG GCA GCG AG-3'; human SNAI2, sense 5'-CGA ACT GGA CAC ACA TAC AGTG-3', anti-sense 5'-CTG AGG ATC TCT GGT TGT GGT-3'; human cyclin D2 (CCND2), sense 5'-ACC TTC CGC AGT GCT CCTA-3', anti-sense 5'-CCC AGC CAA GAA ACG GTCC-3'; human cyclin-dependent kinase inhibitor 1A (CDKN1A), sense 5'-TGT CCG TCA GAA CCC ATGC-3' , anti-sense 5'-AAA GTC GAA GTT CCA TCG CTC-3' ; Bcl2-interacting mediator (BIM), sense 5'-TGG AGC GGA CAT GAT AAG CAT-3' , anti-sense 5'-AGC ACA GGT GTC AAC TAA ATCC-3'; NADPH oxidase activator (NOXA), sense 5'-TGC TAC ACA ATG TGG CGTC-3', anti-sense 5'-ACT TGG ACA TGG CCT CCC TA-3'; and superoxide dismutase 2 (SOD2), sense 5'-TTT CAA TAA GGA ACG GGG ACAC-3', anti-sense 5'-GTG CTC CCA CAC ATC AAT CC-3'. The thermocycling conditions were as follows: 95˚C for 2 min, 95˚C for 5 sec, 60˚C for 30 sec, 72˚C for 30 sec, 40 cycles and dissociation curve. All data were calculated using the 2 -ΔΔCq method (22) .
Immunohistochemistry (IHC)
. IHC was performed on formalin-fixed paraffin-embedded surgical specimens. In brief, tissue samples were fixed with 4% formalin overnight at 4˚C, followed by dehydration in 70, 80, 95, and 100% ethanol. After paraffin embedding, the specimen was cut to 5 to 8 µm thick sections. Tissue sections were dried at 60˚C for 6 h, dewaxed in xylene, rehydrated in a gradient concentration of ethyl alcohol (100, 75, 50 and 25%) and endogenous peroxidase activity was blocked using 3% hydrogen peroxide at 37˚C for 10 min. Small interfering RNA (siRNA) and plasmids. The siRNA (5'-GCG CTT CAT CAA GCT GTT TAC-3') targeting GLP-1R was purchased from Sigma-Aldrich (Merck KGaA). A scrambled siRNA precursor (Scr) was used as the negative control. The siRNAs (10 µg for cells in 10 cm dish, 0.01 µg/µl) were transfected into cells using Lipofectamine ® 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. Lentiviral vectors for the overexpression of GLP-1R were constructed by cloning target genes into pCDH-CMV-MCS-EF1-Puro (System Biosciences, Palo Alto, CA, USA; cat. no. CD510B-1) between the EcoRI and XbaI restriction sites; these vectors were also used for transfection (10 µg for cells in 10 cm dish, 0.01 µg/µl). The FoxO1 S256D and FoxO1 S256A plasmids were constructed by site-directed mutagenesis. Point mutations of FOXO1 were generated by PCR-based mutagenesis using the GeneArt ® Site-Directed Mutagenesis System (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. Briefly, mutagenesis PCR was performed in the reaction mixture, including wild-type (WT)-FoxO1, DNA methylase, Pfx DNA polymerase, and point-mutated primers. The PCR products were transformed into DH5α-T1 E. coli competent cells (Tiangen Biotech, Co., Ltd., Beijing, China), and the positive colonies were analyzed by sequencing. Mutagenesis primer sequences for S256D were forward, 5'-AGG AGA AGA GCT GCA AGT ATG GAC AAC AAC AGT-3' and reverse, 5'-ACT GTT GTT GTC CAT ACT TGC AGC TCT TCT CCT-3'. Primer sequences for S256A were forward, 5'-AGG AGA AGA GCT GCA GCA ATG GAC AAC AAC AGT-3' and reverse, 5'-ACT GTT GTT GTC CAT TGC TGC AGC TCT TCT CCT-3'. For all overexpression experiments, empty pCDH-CMV-MCS-EF1-Puro vector was used as the control, and transfection efficiency was assessed using qPCR and western blot analysis. Further experiments were performed 48 h after transfection.
Transwell assays. Transwell migration and invasion assays were performed in 12-well Transwell plates (8-µm pore size), according to the manufacturer's protocols (Corning Incorporated, Corning, NY, USA). For invasion assays, the bottom of a Transwell chamber was coated with BD Matrigel Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA). Cells (1x10 5 ) in basic culture medium without serum were added to the upper chamber, and the lower chamber was filled with culture medium containing 20% FBS (Invitrogen; Thermo Fisher Scientific, Inc.) as a chemoattractant. Cell migration and invasion were determined after 24 and 48 h, respectively. Cells on the upper side of the chamber were removed from the surface of the membrane by scrubbing, and cells on the lower surface of the membrane were fixed with 4% paraformaldehyde at room temperature for 10 min and stained with 0.1% crystal violet at room temperature for 10 min. The numbers of cells were counted in five randomly selected microscopic fields for each filter using a Nikon Eclipse Ti-s microscope (Nikon Corporation, Tokyo, Japan) at x20 magnification.
Statistical analysis. All data were presented as mean ± standard deviation. All statistical data were based on three separate repeated trials. Statistical analysis was performed with GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Differences between two groups were examined by a Student's two-tailed t-test; multiple comparisons between the groups were performed using Student-Newman-Keuls method following one way analysis of variance. Correlations between two groups were analyzed using a nonparametric Spearman's R test. P<0.05 was considered to indicate a statistically significant difference.
Results

GLP-1R promotes migration and invasion of ICC cells.
It has been indicated previously that GLP-1R is upregulated in ICC tumor tissues (15) . To investigate the role of GLP-1R in ICC cells, GLP-1R expression was measured in different cholangiocarcinoma cell lines by RT-qPCR and western blot analysis. It was indicated that mRNA and protein expression levels of GLP-1R were significantly higher in the ICC cell lines RBE and HCCC-9810 compared with the ECC lines QBC939 and SSP-25 ( Fig. 1A and B) . The expression of GLP-1R was subsequently knocked down in RBE and HCCC-9810 cells by RNA interference to determine the effects of GLP-1R expression on tumor cell migration and invasion. Knockdown of GLP-1R expression was confirmed by RT-qPCR and western blot analysis (Fig. 1C and D) , and the Transwell assay demonstrated that RBE and HCCC-9810 tumor cells exhibited significantly reduced migration and invasion upon GLP-1R silencing (Fig. 1E and F) . Furthermore, overexpression of GLP-1R significantly promoted ICC cell migration and invasion compared with the control (Fig. 1G-J) . These data demonstrated that GLP-1R promotes tumor cell migration and invasion during ICC progression.
GP-1R functions in ICC by regulating FoxO1 signaling.
GLP-1R has been indicated to activate FoxO1 in obese mouse (21) , and activated FoxO1 has been reported to be involved in maintaining cancer stem cells (19) , benefiting tumor metastasis. Considering the effects of GLP-1R on tumor cell migration and invasion, it was speculated that GLP-1R may also modulate FoxO1 in ICC. The expression and phosphorylation state of FoxO1 under GLP-1R knockdown conditions was examined, and it was indicated that suppressed GLP-1R expression resulted in reduced phosphorylation of FoxO1 without affecting the FoxO1 mRNA and protein levels in ICC ( Fig. 2A and B) . The expression of some FoxO1-regulating genes, including CCND2, CDKN1A, BIM, NOXA and SOD2 were also examined using RT-qPCR under GLP-1R knockdown conditions (18) . As expected, GLP-1R knockdown significantly suppressed the expression of genes regulated by FoxO1, compared with the control (Fig. 2C) . To verify this result, a correlation analyses was performed to determine the association between GLP-1R and FoxO1 expression, and phosphorylated FoxO1 expression by IHC of 20 tumor tissues from patients with ICC. IHC analysis revealed that the levels of GLP-1R protein correlated with the phosphorylation levels of FoxO1 (R=0.8167; P=0.0012), but not with FoxO1 expression (R=-0.1858; P=0.5631) (Fig. 2D) . However, the immunohistochemical staining using this antibody was not recommended by the manufacturer. Thus, to confirm IHC results of the present study, western blot analysis was performed. As expected by using another 20 tissues for western blot analysis, GLP-1R protein expression correlated with the levels of phosphorylated FoxO1 (R=0.6098; P=0.0043), but not with FoxO1 expression (R=0.1064; P=0.1064) (Fig. 2E) . Our previous findings indicated that upregulation of GLP-1R in ICC correlated with elevated lymph node metastasis (15); however, we failed to observe any significant correlation between IHC data and clinicopathological factors, which may be due to the small sample size (n=20) in the current study. The aforementioned data suggested that GLP-1R regulates FoxO1 activation. In addition, a mutation (S256D) was constructed in FoxO1 that affects the phosphorylation of FoxO1. The mutation significantly increased the number of invasive cells compared with GLP-1R silencing, but not the abundance of migrating ICC cells under GLP-1R knockdown conditions ( Fig. 2F and G) . This indicated that GLP-1R functions in ICC by modulating the phosphorylation of FoxO1.
Oxaliplatin reverses the effects of GLP-1R on ICC invasion.
Previously, it has been reported that during oxaliplatin treatment, an agonist of GLP-1R functions in ICC tumor suppression (16) , and it has been indicated that the functions of tumor suppressors and oncogenic proteins are reversed during chemotherapy. For example, the effects of p53-mediated senescence on tumor cells could be reversed under chemotherapy (23) (24) (25) . It was speculated that chemotherapy may also alter the functions of GLP-1R in ICC. In the present study, oxaliplatin treatment significantly reduced the migration of tumor cells with or without GLP-1R-silencing. Also, GLP-1R knockdown did not suppress the inhibitory effects of oxaliplatin treatment on the migration of RBE and HCCC-9810 cells, indicating that GLP-1R may not be involved in the oxaliplatin-induced inhibition of migration ( Fig. 3A and B) . In addition, the inhibition of invasion by the GLP-1R knockdown was reversed with oxaliplatin treatment (Fig. 3C and D) . Due to the fact that tumor invasion is associated with epithelial-mesenchymal transformation (EMT), the present study examined whether GLP-1R could regulate the expression of EMT-associated factors, such as CDH1, CDH2, SNAI1, and SNAI2, and whether oxaliplatin treatment could reverse these regulatory effects in ICC. The data showed that when comparing the RBE and RBE-sh groups, GLP-1R knockdown in RBE cells significantly decreased the mRNA levels of CDH2, SNAIl and SNAI2, and upregulated CDH1 (Fig. 3E ), while these effects were reversed upon oxaliplatin treatment (Fig. 3E) . Western blot analysis indicated similar results for the protein levels of EMT-associated factors (Fig. 3F) . FoxO1 has been reported to regulate tumor cell growth; however, the present study did not investigate the effects of FOXO1 and its phosphorylation on ICC cell proliferation. The present study only suppressed the proliferation of ICC cells by using serum-free medium in the Transwell assays. Taking into consideration that changes in tumor growth may also influence the metastatic properties of ICC cells, further investigation is required to determine whether the effects of p-FoxO1 on metastasis depend on its regulation of tumor growth.
Oxaliplatin treatment reduces GLP-1R-induced FoxO1
signaling. The present study investigated whether FoxO1 signaling is involved in oxaliplatin-mediated changes in GLP-1R function. In contrast to the results of the GLP-1R knockdown without oxaliplatin treatment (Fig. 2B) , the mRNA and protein levels of FoxO1 were significantly increased compared with the control, and the phosphorylation state of FoxO1 was notably unaffected in the GLP-1R knockdown RBE cells with oxaliplatin treatment (Fig. 4A and B) . In addition, the FoxO1 S256D mutant with oxaliplatin treatment promoted the invasion of ICC cells, whereas overexpression of WT FoxO1 with oxaliplatin significantly inhibited invasion compared with the control (Fig. 4C) , suggesting that an increase in unphosphorylated FoxO1 may be the key factor in reversing the effects of GLP-1R on invasion. An additional phosphorylation-deficient FoxO1 mutant, FoxO1 S256A, was created. The present study reported that, compared with the corresponding controls, the S256A mutation suppressed the invasion of ICC cells with or without oxaliplatin (Fig. 4D) .
Discussion
Despite the fact that chemotherapy is a well-established cancer treatment, drug resistance has been observed for classical cytotoxic drugs and drugs that target specific molecules (26) . Analyses of the associations between gene-expression profiles of tumor samples and the clinical responses of patients have revealed a strong correlation between EMT-associated gene expression and drug resistance (26) . EMT is the process in which epithelial cells lose their apical-basal polarity and cell-cell adhesion properties, and transition to invasive mesenchymal cells (27) . Cells undergoing EMT displayed reduced expression of epithelial genes, including CDH1 (also known as E-cadherin), increased expression of mesenchymal genes, including CDH2 (also known as N-cadherin), and up regulated expression of a number of regulators of EMT, including SNAIL factors (SNAI1, also known as Snail, and SNAI2, also known as Slug) and FOX proteins (27) (28) (29) (30) . A number of these transcription factors, including FOXC2 and FOXM1, have also been reported to promote drug resistance (31, 32) . FOXC2 was reported to increase the expression of ATP-binding cassette transporters, which enhance drug efflux, thereby promoting drug resistance (33) . However, various members of the FOX transcription factor superfamily have the opposite effect on EMT-associated drug resistance. For example, FOXF2 has been determined to suppress FOXC2-mediated EMT (34) . In the present study, it was demonstrated that the FOX transcription factor FoxO1, may inhibit EMT, but promoted this process in oxaliplatin-treated ICC cells. In addition, it was proposed that the phosphorylation of S256 in FoxO1 may be responsible for altering the function of FoxO1 during drug treatment.
FoxO1 modulates numerous target genes, including genes involved in apoptosis, cell cycle arrest and immune regulation, which suggests that FoxO1 would inhibit cell proliferation in cancer (35) . Upregulation of FoxO1 has been reported to inhibit invasion and metastasis by reversing EMT in HCC (36) . In this study, upregulation of FoxO1 in oxaliplatin-treated ICC cells was observed, and the data suggest that unphosphorylated FoxO1 may reverse EMT-mediated invasion. Previous studies have reported that the effects of FoxO1 depend on its activation, which can be influenced by its abundance, posttranscriptional modification, nuclear-cytoplasmic shuttling and subcellular localization (35) (36) (37) (38) . Among these activating factors, phosphorylation, particularly that of S256, is critical for FoxO1 function (37) . Since FoxO1 S256D and S256A mutations conferred opposing effects on ICC invasion, we suggest that the phosphorylation of S256 may inhibit or reverse the function of FoxO1 in ICC. The phosphorylation of S256 may attenuate FoxO1 function by regulating its degradation (37-39); however, increased phosphorylation of S256 in oxaliplatin-treated ICC cells did not indicate reduced FoxO1 expression levels, and no significant correlation between the FoxO1 level and its phosphorylation in ICC tissues was reported. These data suggest that phosphorylation of S256 affects the function of FoxO1 in ICC via other mechanisms, which will be investigated in future studies.
It has been reported that exendin-4 enhances the phosphorylation of FoxO1 in liver and HCC cells (21) . Geniposide, an agonist of GLP-1R, also increased the levels of cytosolic phosphorylated FoxO1 in pancreatic β-cells and primary cortical neurons to inhibit apoptosis (40, 41) . Our data confirms the effects of GLP-1R on the FoxO1 signaling pathway. In addition, GLP-1R has been reported to regulate the nuclear translocation of activated FoxO1 (42) . Since phosphorylation of S256 may modulate the transactivation and nuclear targeting of FoxO1 (37) (38) (39) , it appears that GLP-1R functions in ICC by regulating the phosphorylation of S256 in FoxO1. In addition, despite that GLP-1-induced FoxO1 activation promotes proliferation in early stage pancreatitis (42), FoxO1 signaling reversed the effects of GLP-1 on proliferation in pancreatic cancer (43) , indicating that GLP-1-induced FoxO1 activation serves different roles under different conditions. Our data is in accordance with this conclusion and suggests that the effects of GLP-1R-associated therapy may vary under different conditions.
Incretin therapy, which involves GLP-1 receptor agonists, has recently become more popular among patients with tumors located in the digestive system (9) . Incretin therapy provides effective glycemic control with a low risk of hypoglycemia, as well as improvements in lipid profiles, weight loss and insulin resistance (44) . However, GLP-1R activation directly enhances proliferation and promotes cell survival in a number of tissues and cells, including B cells, cardiomyocytes, fibroblasts and neurons (45) . In accordance with these oncogenic effects, our data revealed that upregulation of GLP-1R promoted EMT and enhanced tumor invasion. Nevertheless, GLP-1R functions as a tumor suppressor in endometrial cancer and pancreatic cancers (46, 47) . Therefore, GLP-1R serves different roles in different types of cancer, and further research should focus on the underlying mechanisms of GLP-1R in specific cancers. Since the function of GLP-1R was reversed during oxaliplatin treatment, we suggest that agonists of GLP-1R have potential as chemotherapy boosters. For patients that have received surgical or other treatments, administration of these agonists requires further verification. In addition, although gemcitabine and cisplatin are commonly used to treat those with inoperable ICC, patients respond poorly to these chemotherapies (48) . Future studies should focus on combinatorial treatments, including gemcitabine and cisplatin or gemcitabine, cisplatin, and oxaliplatin. In addition, oxaliplatin suppressed EMT in ICC cells and GLP-1R knockdown also suppressed EMT in ICC cells. However, oxaliplatin partially reversed GLP-1R knockdown-induced cell invasion. The potential mechanism of GLP-1R requires further research.
In conclusion, this study indicated that GLP-1R promotes ICC cell migration and invasion in vitro, and this tumor-promoting effect depended on the upregulation of EMT-associated proteins and was mediated by the FoxO1 signaling pathway. The effects of GLP-1R on EMT and invasion were reversed with oxaliplatin, which was associated with reduced phosphorylation of S256 in FoxO1 and an increase in unphosphorylated FoxO1. Our data also suggest that incretin-based therapies may increase the risk of ICC metastasis; thus, such treatments should not be solely used to treat patients with ICC. Additionally, GLP-1R agonists could be used as boosters for certain types of chemotherapies.
The present study indicated GLP-1R is upregulated in ICC, and incretin-based therapies may increase the risk of ICC metastasis. Aberrant upregulation of GLP-1R promotes ICC cell migration and invasion. Therefore, it should not be used solely for the treatment of patients with diabetes and ICC. In addition, oxaliplatin was proposed to reverse the incretin-mediated promotion of tumor invasion by altering FoxO1 signaling in ICC.
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